treatment
Treatment of Cognitive Impairment in Schizophrenia
Impairments in everyday functional outcomes are very common in people with schizophrenia and these impairments are associated with deficits in cognitive functioning. Cognitive enhancement has been proposed as a pathway to disability reduction. This pathway has been clearly defined in terms of the required clinical trials methods, with primary (cognitive) and secondary (functional) outcome measures well validated. Second generation (Newer, Atypical) antipsychotic medications have been thoroughly evaluated with their cognitive enhancement potential. Read more about this session.
2010-2011 Psychiatric Pharmacy Review Course - ACPE Credit Only
The Psychiatric Pharmacy Review Course (Review Course) is an excellent course of study and resource for those seeking a review of psychopharmacology and current standards of care. Read more about this session.
Effects of Large Doses of Arachidonic Acid Added to Docosahexaenoic Acid on Social Impairment in Individuals With Autism Spectrum Disorders: A Double-Blind, Placebo-Controlled, Randomized Trial
Abstract: Autism spectrum disorders are a neurodevelopmental disorders with reduced cortical functional connectivity relating to social cognition. Polyunsaturated fatty acids arachidonic acid (ARA) and docosahexaenoic acid (DHA) may have key role in brain network maturation. In particularly, ARA is important in signal transduction related to neuronal maturation. Supplementation with larger ARA doses added to DHA may therefore mitigate social impairment.
US Psychiatric Residents’ Treatment of Patients With Bipolar Disorder
Abstract: We aimed to evaluate the practice patterns of US postgraduate year (PGY) levels 3 and 4 psychiatric residents in the treatment of patients with bipolar disorder (BD) types I and II. We also aimed to determine whether confidence in prescribing mood stabilizers is associated with residents’ practice patterns. The residency training directors of 182 Accreditation Council for Graduate Medical Education–accredited US psychiatric residencies were solicited for study participation via e-mail.
Combination of Antidepressants in the Treatment of Major Depressive Disorder: A Systematic Review and Meta-Analysis
Abstract: The objective was to perform a systematic review and meta-analysis of studies that assessed the effect of the combination of antidepressants from the beginning of the treatment of major depressive disorder. Studies were retrieved from PubMed (1966 to August 2010), Cochrane Library (August 2010), Embase (1980 to August 2010), PsycINFO (1980 to August 2010), Lilacs (1982 to August 2010), clinical trials registry, thesis database (www.capes.gov.br ), and secondary references.
An Exploratory, Open Trial of Fluoxetine Treatment of Juvenile Fibromyalgia
No abstract available
Bupropion XL for the Sustained Treatment of Trichotillomania
No abstract available
[Seminar] Major depressive disorder: new clinical, neurobiological, and treatment perspectives
In this Seminar we discuss developments from the past 5 years in the diagnosis, neurobiology, and treatment of major depressive disorder. For diagnosis, psychiatric and medical comorbidity have been emphasised as important factors in improving the appropriate assessment and management of depression. Advances in neurobiology have also increased, and we aim to indicate genetic, molecular, and neuroimaging studies that are relevant for assessment and treatment selection of this disorder.